Clinilabs Selected for a Phase II Study of Major Depressive Disorder

Article

Company News Release

Clinilabs, a contract research organization that provides early-stage and specialty clinical drug development services to industry, announced that they have been selected to conduct a Phase II clinical research study of an investigational medication in patients with Major Depressive Disorder.
 
The trial will examine the effects of an investigational medication in treatment resistant patients who are experiencing a current episode of depression. This is Clinilabs’ fifth study in this therapeutic area. Dr. Stephen Murray, Clinilabs’ Chief Medical Officer states: “Major Depressive Disorder is a debilitating disease that carries with it both emotional and physical symptoms. I am pleased to be involved in a clinical trial that is assessing a novel medication that may combat this condition.”
 
Enrollment for this study has begun. Referrals from physicians and other healthcare providers are welcomed. Individuals in the New York City Metro area who suffer from Major Depressive Disorder can contact our call center at 212-994-4567 to prequalify. Additional information may also be found by visiting www.clinilabs.com/mdd.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.